drugset / Trial / NCT04680143

Systemic Erythropoietin Injection in Patients Having Optic Atrophy

NCT04680143

Phase 1/2 Completed 10 enrolled Alexandria University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy.

Timeline

Start
2020-09-01
Primary completion
2021-03-01
Completion
2021-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 10000 iu Subcutaneous

Indications